Observers Fear Funding Practices May Spell The Death Of Innovative Grant Proposals

Point Grants:NIGMS' Marvin Cassman agrees that risky proposals don't get funded. The traditional, romantic notion of scientific research is of a glorious, serendipitous journey into the unknown. But this ideal is belied, in the perception of many scientists, by the apparent reality that much of what gets funded these days is less exploratory and more predictable_cloning and sequencing a gene, for example. While not denying the importance of such predictable studies, the scientific community s

Written byBilly Goodman
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

The traditional, romantic notion of scientific research is of a glorious, serendipitous journey into the unknown. But this ideal is belied, in the perception of many scientists, by the apparent reality that much of what gets funded these days is less exploratory and more predictable_cloning and sequencing a gene, for example.

While not denying the importance of such predictable studies, the scientific community shares a nearly universal conviction that proposals for risky, innovative research stand very little chance of being funded by federal granting agencies. Grant administrators themselves acknowledge that unconventional ideas or those with a short or disputed track record rarely make the cut.

"Controversial areas will not do as well as applications where there is broad consensus," states Marvin Cassman, acting director of the National Institute of General Medical Sciences (NIGMS). "Given the degree of difficulty in funding these days, some applications [in areas] where there is [scientific] ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies